AdeTherapeutics Sets New Benchmark for Fibrosis Treatment, Attracts Global Interest

  AdeTherapeutics Sets New Benchmark for Fibrosis Treatment, Attracts Global
  Interest

AdeTherapeutics, Inc. – Breaking Ground in Fibrosis Treatment – Exhibiting at
       BIO International Convention – April 22-25, 2013 – Chicago, Ill.

2013 BIO International Convention Booth #3831

Business Wire

CHICAGO -- April 23, 2013

AdeTherapeutics, Inc., a world leader in developing patented products that
reduce adhesion complications related to surgery, today announced that its
innovative approach to fibrosis prevention is attracting notable physicians
and partnerships worldwide.

“We have patented, developed and brought into human testing a novel approach
and biopharmaceutical investigational drug candidate (peptide), that when
locally administered, activates the body’s internal repair mechanisms  and
accelerates the pace at which healing occurs,” stated Sanj Singh, CEO of
AdeTherapeutics. “Our approach in dealing with fibrosis and fibrotic diseases
is being explored by global leaders in the areas of gynecology, spinal
peritoneal fibrosis and ophthalmology – all of which are estimated at over $30
billion.”

In addition to securing partnerships in key disciplines, the company’s
revolutionary approach has also attracted the most recognized professionals in
the field, including recent members Dr. James Greenberg (Gynecologist at
Brigham & Women’s Health), Dr. Raphael Guzman (Stanford and Basel Stem Cell)
and Dr. Joanne Bargman (President, International Society of Peritoneal
Dialysis).

"Post-operative adhesions are a huge problem for which there is currently no
good solution. AdeTherapeutic's novel approach is extremely exciting as a
potential treatment," stated Dr. James Greenberg, Medical Advisory Board
member specializing in Obstetrics and Gynecology with expertise in several
areas. "For me, the use of a solution as opposed to a barrier or medical
device is a tremendous breakthrough. I believe if this approach shows efficacy
in Phase II trials it could set a new standard of care in gynecology pelvic
surgeries."

Progress continues globally with a joint collaboration with Royal DSM N.V. in
spinal to address failed back surgery syndrome that will result in clinical
trials in Europe this year. Additionally, with preclinical work about to
commence with one of the leading authorities in fibrosis, Dr. Mark Sherwood at
University of Florida, Gainesville, a safer anti-fibrotic may finally be
available to ophthalmologists.

AdeTherapeutics will tout its fibrosis prevention benchmark at the 2013 BIO
International Convention in the Canada Café in the Saskatchewan Biosciences
Booth #3831. CEO Sanj Singh is presenting at the BIOTECanada showcase series
on Wednesday, April 24^th at 1:30pm.

For more information, visit http://www.adetherapeutics.com/.

                          All trademarks recognized.

Contact:

AdeTherapeutics, Inc.
Sanj Singh, +1-306-261-5189
sanj@adetherapeutics.com
or
BroadPR, Inc.
Tracy Wemett, +1-617-868-5031
tracy@broadpr.com
 
Press spacebar to pause and continue. Press esc to stop.